Philip Lee Healthcare, Pharmaceutical and Life Science Update Q4 2022

Key Contact: Ronan Dunne – PartnerMarie Kinsella – Partner

Welcome to the latest update from the Philip Lee Healthcare, Pharmaceutical and Life Science group in respect of the fourth quarter of 2022.
This update covers a range of topics:

General Regulatory – Ireland
1. Guidance issued by the HPRA on appeals under Cosmetic Products Regulation 2013

General Regulatory – EU

2. European Commission adopts Report on implementation of the Organ Transplantation Directive

3. Common Specifications have been introduced for Devices without an Intended Medical Purpose

4. Regulation on European Centre for disease prevention and control published in Official Journal

5. Regulation on serious cross border threats to health published in the Official Journal

6. Reclassification of Certain devices without an Intended Medical Purpose

7. Proposal to extend Transitional Deadlines for the Medical Devices Regulation and the In Vitro Diagnostic Devices Regulation

8. New European Commission Expert Group on Public Health

9. European Commission Changed Labelling Requirements for Investigational Medicinal Products

10. Publication of European Commission note on the revision of EU pharmaceutical legislation
Global Insights

11. European Health Data Space

12. Novo Nordisk and Microsoft announce collaboration to accelerate drug discovery

13. Report on EU Covid-19 Vaccine Procurement Performance

14. European Commission Work Programme 2023: Life Sciences Initiative

15. Transformation of the General Product Safety Directive 2001

16. Publication of “Health at a Glance: Europe 2022” by the European Commission and the OECD

17. Quality Innovation Expert Group established by EMA
Data Protection

18. Public Consultations launched by the EMA on data quality and real-world data sources

19. Public Consultations launched by the EMA on data quality and real-world data sources

20. EMA publishes ICH guideline E19 on selective safety data collection in specified clinical trials

21. Highlights of fifth bilateral meeting between EMA and Medicines for Europe

22. Positive Opinion issued by the EMA on second adapted Spikevax Vaccine

23. Cominarty and Spikevax vaccines recommended by EMA for children from six months

24. CJEU makes preliminary ruling on M2Beautè

25. Updated guidance on applications for orphan designation published by the European Commission

26. European Commission proposes new EU Global Health Strategy to improve global health security

27. Joint European Commission and World Health Organisation announcement on global health co-operation

28. Council Recommendation on a new EU approach on cancer screening published in Official Journal

To read the full update see: Philip Lee – Healthcare Newsletter Q4 2022.

For further information in relation to this article please contact Ronan Dunne or Marie Kinsella.


News and insights

M&A Insights H1 2023 – A cross-border deal insight guide

M&A Insights H1 2023 – A cross-border deal insight guide

Key Contacts: Eoghan Doyle - Partner  |  Andrew Tzialli - Partner We are delighted to introduce the fifth edition of the Philip Lee M&A Insights guide. In this edition, we review deal activity across H1 2023, and consider the outlook for the rest of the year...

read more
The Web3 passport

The Web3 passport

Key Contacts: Andrew Tzialli - Partner  | Head of blockchain and crypto assets, Andrew Tzialli, spoke to the Web3 passport in their latest podcast to discuss the world of blockchain and digital assets. The Web3 passport podcast explores areas such as Web3, blockchain,...

read more
Share This